Some uses of predictive probability of success in clinical drug development
|
| Title | Some uses of predictive probability of success in clinical drug development |
| Authors | |
| Abstract | Predictive probability of success is a (subjective) Bayesian evaluation of the prob- ability of a future successful event in a given state of information. In the context of pharmaceutical clinical drug development, successful events relate to the accrual of positive evidence on the therapy which is being developed, like demonstration of su- perior efficacy or ascertainment of safety. Positive evidence will usually be obtained via standard frequentist tools, according to the regulations imposed in the world of pharmaceutical development.Within a single trial, predictive probability of success can be identified with expected power, i.e. the evaluation of the success probability of the trial. Success means, for example, obtaining a significant result of a standard superiority test.Across trials, predictive probability of success can be the probability of a successful completion of an entire part of clinical development, for example a successful phase III development in the presence of phase II data.Calculations of predictive probability of success in the presence of normal data with known variance will be illustrated, both for within-trial and across-trial predictions. |
| Publisher | PREX |
| Date | 2013-03-21 |
| Source | Epidemiology, Biostatistics and Public Health Vol 10, No 1 (2013) |
| Rights | • The authors warrant that the manuscript (or its essential substance) has not been published in any language or format and has not been submitted elsewhere for print or electronic publication consideration• The authors warrant that the manuscript does not contain any material the publication of which would violate any copyright or other personal or proprietary right of any person or entity• The authors warrant that there aren’t potential conflicts of interest• The authors will obtain and include with the manuscript written permission from any respective copyright owners for the use of any textual, illustrative, or tabular materials that have been previously published or are otherwise copyrighted and owned by third parties.When the article is accepted for publication. The authors, hereby agree to transfer to Prex s.p.a. all rights, including those pertaining to electronic forms and transmissions, under existing copyright laws.© Prex SpA |